Mineralys Therapeutics, Inc. MLYS Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $1.03M+55.1% | $664K+3.3% | $643K-77.6% | $2.87M-73.1% | ||
| $661.39M+222% | $205.35M-17.6% | $249.1M+121% | $112.81M— | ||
| $38K-28.3% | $53K— | $0— | —— | ||
| $1.82M-7.7% | $1.98M-3.5% | $2.05M+659% | $270K— | ||
| $661.81M+221% | $205.9M-18.2% | $251.64M+120% | $114.44M— | ||
| $2.02M+321% | $479K-20.3% | $601K-68.5% | $1.91M— | ||
| $15.11M+3.2% | $14.65M+39.7% | $10.48M+29.9% | $8.07M— | ||
| 500M0.0% | 500M0.0% | 500M+56.7% | 319M— | ||
| -$457.17M-51.1% | -$302.52M-143% | -$124.71M-136% | -$52.81M— | ||
| $646.69M+238% | $191.26M-20.7% | $241.15M+561% | -$52.27M-128% | ||
| $661.81M+221% | $205.9M-18.2% | $251.64M+120% | $114.44M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Mineralys Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 44.33 — current assets exceed current liabilities.
- Where does Mineralys Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.